Opko Health has unveiled its revenue forecasts for 2025, projecting total revenues to fall between $675 million and $700 million. The company's breakdown of this revenue expects services to bring in $400 million to $425 million, while product sales are anticipated to be between $165 million and $175 million. Additionally, other revenues, which include a Pfizer gross profit share and BARDA income, are estimated at $80 million to $95 million.

Reuters reported that the company's total costs and expenses for 2025 will likely range from $825 million to $875 million, not accounting for non-recurring charges related to the restructuring of BioReference Health. Research and development costs are projected to be $120 million to $140 million, with a portion offset by BARDA funding. Depreciation and amortization are expected to add up to $90 million.

Strategically, Opko Health aims to enhance its pharmaceutical pipeline and maintain significant R&D investments, working collaboratively with industry giants like Pfizer and Merck. The company is also actively seeking partnerships to further develop its product portfolio and boost its financial standing by the year 2025.